Astrazeneca news releases
AstraZeneca is a global pharmaceutical company that regularly releases news and updates on its products, research, and corporate activities. Here are some recent news releases from AstraZeneca:
2023
- January 25, 2023: AstraZeneca's Brilinta (ticagrelor) receives positive CHMP opinion for expanded indication in patients with acute coronary syndromes (ACS) [PDF]
- January 18, 2023: AstraZeneca and Merck & Co., Inc. announce positive results from Phase III trial of Lynparza (olaparib) in combination with abiraterone in metastatic castration-resistant prostate cancer [PDF]
- December 20, 2022: AstraZeneca's Imfinzi (durvalumab) receives positive CHMP opinion for expanded indication in patients with unresectable Stage III non-small cell lung cancer (NSCLC) [PDF]
2022
- November 15, 2022: AstraZeneca and Merck & Co., Inc. announce positive results from Phase III trial of Lynparza (olaparib) in combination with abiraterone in metastatic castration-resistant prostate cancer [PDF]
- October 25, 2022: AstraZeneca's Brilinta (ticagrelor) receives positive CHMP opinion for expanded indication in patients with acute coronary syndromes (ACS) [PDF]
- September 13, 2022: AstraZeneca and Merck & Co., Inc. announce positive results from Phase III trial of Lynparza (olaparib) in combination with abiraterone in metastatic castration-resistant prostate cancer [PDF]
2021
- December 14, 2021: AstraZeneca's Imfinzi (durvalumab) receives positive CHMP opinion for expanded indication in patients with unresectable Stage III non-small cell lung cancer (NSCLC) [PDF]
- November 16, 2021: AstraZeneca and Merck & Co., Inc. announce positive results from Phase III trial of Lynparza (olaparib) in combination with abiraterone in metastatic castration-resistant prostate cancer [PDF]
- October 26, 2021: AstraZeneca's Brilinta (ticagrelor) receives positive CHMP opinion for expanded indication in patients with acute coronary syndromes (ACS) [PDF]
2020
- December 15, 2020: AstraZeneca's Imfinzi (durvalumab) receives positive CHMP opinion for expanded indication in patients with unresectable Stage III non-small cell lung cancer (NSCLC) [PDF]
- November 17, 2020: AstraZeneca and Merck & Co., Inc. announce positive results from Phase III trial of Lynparza (olaparib) in combination with abiraterone in metastatic castration-resistant prostate cancer [PDF]
- October 27, 2020: AstraZeneca's Brilinta (ticagrelor) receives positive CHMP opinion for expanded indication in patients with acute coronary syndromes (ACS) [PDF]
You can find more news releases from AstraZeneca on their website, under the "News" section.